Evolocumab lowers LDL cholesterol by more than 50% (NEJM) PDF Print
NEJM: Among the 901 patients included in the primary analysis, the overall least-squares mean (+/-SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0 +/-2.1% (P<0.001).

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.